International Congress on the Future of Breast Cancer East | Conference

CDK4/6 Inhibitors Could Fill Treatment Void for Patients with HR+/HER2- Early Breast Cancer

July 22nd 2022

Joyce O'Shaughnessy, MD, outlines the current role and ongoing research of CDK4/6 inhibitors in the treatment of patients with hormone receptor–positive, HER2-negative early stage breast cancer.

Optimized Therapy Requires More Than Binary Understanding of HER2 Positivity in Metastatic Breast Cancer

July 16th 2022

Neratinib-based combinations, antibody-drug conjugates, and bispecific antibodies represent novel and effective treatment options for patients with pretreated HER2-mutant and HER2-low metastatic breast cancer, but the successful integration of these regimens into care will require further investigation into current definitions of HER2 positivity.

ADCs With Non-Cytotoxic Payloads May Represent the Future of HER2+ Breast Cancer Treatment

July 16th 2022

The emergence of novel agents like trastuzumab deruxtecan and tucatinib in the HER2-positive breast cancer treatment paradigm have served to markedly improve outcomes for those with this disease, according to Mark Pegram, MD, who added that the future looks bright.

Intrinsic Tumor Subtyping Is Key To Breast Cancer Treatment

July 15th 2022

Charles M. Perou, PhD, discusses the role of intrinsic tumor subtyping in treatment decisions and outcomes for patients with breast cancer.

Treatment Strategies Evolve With Increased Disease Specification in HER2+ Breast Cancer

July 15th 2022

Adrienne G. Waks, MD, highlights clinical trials that are studying emerging treatment escalation and de-escalation strategies in early stage HER2-positive breast cancer, elaborates on the future of immunotherapy in this setting, and explains the significance of establishing new biomarkers.

Ovarian Function Suppression Drives Chemotherapy Benefits in Premenopausal HR+/HER2- Breast Cancer

July 15th 2022

Premenopausal patients with early hormone receptor–positive, HER2-negative breast cancer can benefit from chemotherapy, although it is still debatable whether that benefit stems from the chemotherapy itself or the ovarian function suppression that happens as a result of chemotherapy.

Dr. Waks on the Continued Evaluation of Immunotherapy in HER2+ Breast Cancer

July 14th 2022

Adrienne G. Waks, MD, discusses the continued evaluation of immunotherapy in HER2-positive breast cancer.

Dr. Kalinsky on Ovarian Function Suppression and Chemotherapy in HR–Positive Breast Cancer

July 14th 2022

Kevin Kalinsky, MD, MS, discusses the relationship between ovarian function suppression and chemotherapy benefits in premenopausal patients with HR–positive breast cancer.

Dr. Gradishar on the Significance of Drug Development in HER2+ Breast Cancer

July 21st 2021

William Gradishar, MD, discusses the significance of drug development in HER2-positive breast cancer.

Novel Vaccine Combos Represent a Promising Treatment Approach in Breast Cancer

July 19th 2021

The future of therapeutic vaccines in breast cancer will be dependent on their use in combination with standard anticancer drugs, checkpoint antagonists, and distinct checkpoint inhibitors, Leisha A. Emens, MD, PhD.

Dr. Tolaney on Tailoring HER2-Directed Therapy in Breast Cancer

July 19th 2021

Sara M. Tolaney, MD, MPH, discusses tailoring HER2-directed therapies in the treatment of patients with breast cancer. 

SERDs Represent the Next Generation of ER-Targeting Therapy in Breast Cancer

July 19th 2021

Selective estrogen receptor degraders are becoming increasingly important in the treatment of ER-positive metastatic breast cancer.

Chemoimmunotherapy Shakes Up Metastatic and Early-Stage TNBC

July 17th 2021

Chemoimmunotherapy combinations have transformed the treatment landscape for patients with triple-negative breast cancer, but balancing potential efficacy with the risk of toxicity with these regimens is critical in both the metastatic and early-stage settings.

Tolaney Spotlights Tailoring Therapy by Risk in HER2+ Breast Cancer

July 16th 2021

By adapting adjuvant therapy based on responses to preoperative therapy, investigators may be able to change long term outcomes for patients with HER2-positive breast cancer, creating a paradigm shift in the space.

Dr. Kalinsky on Therapeutic Options Beyond Chemotherapy in High-Risk Breast Cancer

July 16th 2021

Kevin Kalinsky, MD, MS, discusses treatment options beyond chemotherapy in patients with high-risk breast cancer.

Leveraging CDK4/6 Inhibitors in Earlier Settings to Boost Outcomes in HR+ Breast Cancer

July 17th 2020

Angela DeMichele, MD, MSCE, shares how to utilize available data with CDK4/6 inhibitors in the neoadjuvant and adjuvant settings to optimize outcomes for patients with hormone receptor–positive breast cancer.

Dr. Mamounas on Recurrence Rates in Breast Cancer

July 17th 2020

Terry P. Mamounas, MD, MPH, FACS, discusses common recurrence rates in breast cancer.

Key Data Inform Treatment Decisions in Early HER2+ Breast Cancer

July 17th 2020

The growing number of treatments within the HER2-positive breast cancer armamentarium signals a need to redefine and tailor neoadjuvant and adjuvant strategies to individual patients.

Dr. Tolaney on Deescalating Therapy in Stage I HER2+ Breast Cancer

July 17th 2020

Sara M. Tolaney, MD, MPH, discusses appropriately deescalating treatment to reduce toxicities in stage I HER2-positive breast cancer.

Metastatic HER2+ Breast Cancer Treatment Must Move to Personalized Approach

July 17th 2020

The optimal sequence of therapies for patients with metastatic HER2-positive breast cancer must be an individualized one, and should be dependent on the presence and/or level of central nervous system disease.